

# AMC 2023

## PRE: THURSDAY 23 MARCH

1.00 - 5.30	<b>DELEGATE ARRIVAL &amp; CHECK-IN</b> <i>Boulevard Foyer, 1.00 - 5.00</i> <i>Collect your name tag for AMC 2023 and the MASC Trials ASM</i>	
2.00 - 5.38		<b>Melanoma and Skin Cancer (MASC) Trials 2023 Annual Scientific Meeting</b> <i>2.00 - 5.38, Boulevard B1</i>  <a href="http://www.masc.org.au/asm-2023">www.masc.org.au/asm-2023</a>

## DAY 1: FRIDAY 24 MARCH

8.30 – 8.45	<b>Opening of the Conference - Boulevard Auditorium</b> .1 Acknowledgement of Country - Mark Smithers, Brisbane & H. Peter Soyer, Brisbane	
-------------	---	--

8.45 - 10.15	<b>1. Plenary 1: Prevent, diagnose and support - Boulevard Auditorium</b> Chairs: Mark Smithers, Brisbane & H. Peter Soyer, Brisbane .1 Evolution of melanoma diagnosis - Harald Kittler, Vienna (Austria)  .2 Building research capacity towards early detection of melanoma - Monika Janda, Brisbane  .3 Improving skin cancer management with artificial intelligence - Victoria Mar, Melbourne  .4 Panel discussion - Harald Kittler, Monika Janda and Victoria Mar  .5 State of the nation report and the consumer – Victoria Beedle, Gold Coast  .6 Consumer panel - Karen van Gorp, Adelaide Rod Flude, Brisbane Tamara Dawson, Melbourne	
--------------	---	--

10.15 - 10.45	Morning Break	
---------------	---------------	--

### CONCURRENT SESSIONS 1

10.45 - 12.15	<b>1.1 Melanoma: burden, control, policy – Boulevard Auditorium</b> Chairs: David Whiteman, Brisbane & Anne Cust, Sydney .1 Trends in melanoma incidence in Australia - Catherine Olsen, Brisbane  .2 The economic burden of melanoma and keratinocytic skin cancer in Australia - Louisa Gordon, Brisbane  .3 Skin checks in general practice: The upfront and downstream patterns and costs - David Goldsbury, Sydney  .4 Does methotrexate increase melanoma risk? - Mabel Yan, Melbourne  .5 Balancing the risks and benefits of sun exposure: recognising the diversity of Australia's population sun exposure guideline update - Rachel Neale, Brisbane  .6 Panel discussion - Catherine Olsen, Louisa Gordon, David Goldsbury, Mabel Yan, Rachel Neale	<b>1.2 Diagnosis melanoma, what now? - Boulevard B1</b> Chairs: Sydney Ch'ng, Sydney & James Clover, Ireland <b>Diagnostic biopsy impact on definitive treatment</b> .1 Pathologist view - Louise Jackett, Melbourne  .2 Surgeon's view - Gerard Bayley, Brisbane  .3 Discussion - Louise Jackett, Gerard Bayley  .4 Treatment of primary "dermal" melanoma - Robyn Saw, Sydney  .5 Treatment of primary desmoplastic melanoma - Ajay Chauhan, Brisbane  .6 Quality performance indicators in melanoma - Richard Martin, Auckland (New Zealand)  .7 Discussion - Robyn Saw, Ajay Chauhan, Richard Martin	<b>1.3 Basic science 1: Genetics/genomics – Boulevard B2</b> Chairs: Mitchell Stark, Brisbane & Felicity Newell, Brisbane .1 The genomics of acral and mucosal melanomas - Felicity Newell, Brisbane  .2 The genomic landscape of melanocytic naevi and adjacent skin - Mitchell Stark, Brisbane  .3 On the role of aneuploidy in primary cutaneous melanoma - Ismael Vergara, Sydney  .4 The female survival advantage in melanoma – are X-linked epigenetic regulators responsible? - Jessamy Tiffen, Sydney  .5 Investigating lncRNAs derived from skin cancer-relevant cells – Matthew Law, Brisbane  .6 Spatial transcriptomics of early invasive melanomas reveals molecular determinants of patient survival - Chenhao Zhou, Brisbane  .7 Targeting epigenetic enzymes to boost immunotherapy response in melanoma – Jason Lee, Brisbane  .8 3D total-body-imaging reveals hereditary melanoma genes POT1, POLE and BAP1 confer significantly higher naevus counts than CDKN2A - Ellie Maas, Brisbane
---------------	---	---	--

12.15 - 1.30	Lunch Break	
--------------	-------------	--

### INDUSTRY SESSIONS - 12.30 - 1.15

	<b>Where in the world does Nivolumab+Relatlimab fit? Personalised treatment decisions in first line metastatic melanoma</b> <i>- Boulevard Auditorium</i> .1 Victoria Atkinson, Brisbane .2 Matteo Carlino, Sydney .3 Rachel Roberts-Thomson, Adelaide <i>Sponsored by Bristol-Myers Squibb Australia</i>	
--	--	--

### CONCURRENT SESSIONS 2

1.30 - 3.00	<b>2.1 Overdiagnosis: population perspectives, potential solutions – Boulevard Auditorium</b> Chairs: Rachel Neale, Brisbane & Erin McMeniman, Brisbane .1 Overdiagnosis in melanoma: What are the epidemiology studies telling us? - David Whiteman, Brisbane  .2 Do we need to rethink the diagnoses melanoma in-situ and severely dysplastic naevus? A review of evidence - Katy Bell, Sydney  .3 Diagnostic drift- does it exist and what can we do about it? - Blake O'Brien, Brisbane  .4 Building evidence for a targeted national screening program for melanoma - Anne Cust, Sydney  .5 Panel Discussion - David Whiteman, Katy Bell, Blake O'Brien, Anne Cust	<b>2.2 Surgery and regional treatment - Boulevard B1</b> Chairs: Robyn Saw, Sydney & Trent Cross, Brisbane .1 The pathologist role in sentinel node biopsy - Robert Rawson, Sydney  .2 The radiologist role in sentinel node biopsy - Kevin London, Sydney  .3 The surgeon: performing the sentinel node biopsy - Richard Martin, Auckland (NZ)  .4 Head and neck sentinel node biopsy - Sam Yang, Brisbane  .5 Discussion - Robert Rawson, Kevin London, Richard Martin, Sam Yang	<b>2.3 Basic science 2: immunology – Boulevard B2</b> Chairs: Karen Sheppard, Melbourne & Nikolas Haass, Brisbane .1 Early detection of melanomas using circulating tumour-specific antibodies - Jessica Da Gama Duarte, Melbourne  .2 Single-cell sequencing and multicolor immunofluorescence define novel subsets of tumor-infiltrating lymphocytes in uveal melanoma - Jonas Nilsson, Perth  .3 Is location enough? Investigating the role for CD8+ resident memory T cells in metastatic melanoma - Paul Neeson, Melbourne  .4 Expression of novel drug targets in metastatic melanoma patients treated with anti-PD-1-based therapies - Tuba Nur Gide, Sydney  .5 Classification of the tumour immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies - Nurudeen Adegoke, Sydney
-------------	---	--	--

		.6 Do we need to do a complete regional node dissection for metastatic melanoma nodal disease in 2023? - Andrew Barbour, Brisbane	.6 Sequencing BRAFI/MEKI after aPD1/aCTLA4 results in a potent immune microenvironment - Riyaben Patel, Melbourne
		.7 The role of regional surgery for merkel cell carcinoma - Chris Allan, Brisbane	.7 Overcoming immune checkpoint inhibitor resistance to improve melanoma therapy – Nikolas Haass, Brisbane
			.8 Targeting replication stress as an immunotherapy in melanoma – Zhen Zeng, Brisbane
3.00 - 3.30	Afternoon Tea		
3.30 - 5.00	<b>CONCURRENT SESSIONS 3</b>		
	<b>3.1 Free Communication Session 1 – Boulevard Auditorium</b> <b>Chairs:</b> Shahneen Sandhu, Melbourne & Jason Miller, Brisbane .1 The association between histopathological characteristics and death from thin (≤1.00 mm) melanoma: a population-based nested case-case study - Magdalena Claeson, Gothenburg (Sweden) .2 Automated assessment of tumour infiltrating lymphocytes informs mortality in thin melanoma - Samuel Tan, Brisbane .3 Results from a randomised trial of post-operative radiation therapy following wide excision of neurotropic melanoma of the head and neck (RTN2 trial 01.09) - Mark Pinkham, Brisbane .4 Modality of detection of nodal recurrence in sentinel node positive patients, in whom completion lymph node dissection was omitted - Caroline Gjørup, Sydney .5 Evaluation of leg lymphoedema after inguinal and ilio-inguinal lymphadenectomy for melanoma. Results from a prospective randomised trial - Teresa Lee, Sydney .6 Effects of neoadjuvant systemic therapy on surgical outcomes of lymph node dissections in stage III melanoma. - Lisanne Zijker, Amsterdam (The Netherlands) .7 Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma- a mixed-methods systematic review - Julia Lai-Kwon, Melbourne .8 Chemokine analysis in patients with metastatic uveal melanoma suggests a role for CCL21 signaling in combined epigenetic therapy and checkpoint immunotherapy - the PEMDAC trial - Lars Ny, Gothenburg (Sweden)	<b>3.2 Free Communication Session 2 - Boulevard B1</b> <b>Chairs:</b> Catherine Olsen, Brisbane & Pablo Fernandez-Penas, Sydney .1 The value of research cohorts: melanoma research Victoria's outcomes - Kristy Barnes-Cullen, Melbourne .2 Characteristics of open-access skin cancer image datasets: implications for equitable digital health - David Wen, Oxford (UK) .3 Variations in healthcare use for individuals diagnosed with invasive melanoma in Queensland, Australia - Daniel Lindsay, Brisbane .4 Mediators of changes in melanoma prevention and early detection behaviours in response to a genomic risk intervention in an Australian population sample - Amelia Smit, Sydney .5 Risk of melanoma recurrence 7-years after diagnosis of a high-risk primary tumour - Lena Von Schuckmann, Brisbane .6 Monitor or excise? The dilemma of digital imaging - Charlotte Cox, Brisbane .7 What is the real-world melanoma miss rate in a public hospital dermatology service? - Alexander Anderson, Sydney .8 New and small invasive melanoma a common occurrence in tertiary practice: can AI help? - Pascale Guitera, Sydney .9 Trends and patterns of care of sentinel node biopsy in cutaneous melanoma: a population-based study in Queensland - Jessica Wong, Brisbane	<b>3.3 Basic science 3: Melanoma biology + free papers – Boulevard B2</b> <b>Chairs:</b> Elin Gray, Perth & Helen Rizos, Sydney .1 Cell-to-cell communication in uveal melanoma metastases - Elin Gray, Perth .2 Stable isotope tracing as a tool to study melanoma metabolism - Aparna Rao, Melbourne .3 Melanoma phenotypic plasticity and resistance to anti-PD1 therapy - Mike Eccles, Dunedin (New Zealand) .4 Elucidating the tumour vasculature to better understand melanoma - Claudine Bonder, Adelaide .5 Desmoglein-2, an unsuspected regulator of tumour vasculature and immune response in melanoma - Michaelia Cockshell, Adelaide .6 Targeting tumour vascularisation through endothelial-specific Sox9 deletion reduces melanoma metastasis - Ghazaleh Hashemi, Brisbane .7 Inhibiting PRMT5: A novel target for the treatment of melanoma – Lydia Lim, Melbourne .8 Single cell profiling of tumour biopsies reveals molecular heterogeneity of response – Esther Lim, Sydney
5.00 - 6.30	Welcome Reception Sponsored by MedAdvance		
<b>DAY 2: SATURDAY 25 MARCH</b>			
7.30 - 8.45	<b>MORNING SESSIONS</b>		
	<b>Breakfast Session: Optimising care and treatment for BRAF-mut melanoma patients - Boulevard Auditorium</b> A deep dive into the latest published data on BRAF/MEK inhibitors & the key clinical challenges managing patients with advanced BRAF-mutant melanoma facing us today.  <b>Chair:</b> Georgina Long, Sydney .1 <b>Speaker:</b> Reinhard Dummer, Zurich (Switzerland) Virtual .2 <b>Panel:</b> Andrew Haydon, Melbourne & Megan Lyle, Cairns  Sponsored by Pierre Fabre	<b>Workshop: Dermoscopy – Boulevard B1</b> Potential biases and risks are associated with the use of dermatoscopy and the interpretation of skin lesions should always include contextual information.  In this workshop "eureka" moments and "wow" experiences including hunting BIG Game – Melanomas that Matter – will be discussed.  <b>Chair:</b> H. Peter Soyer, Brisbane .1 Harald Kittler, Vienna (Austria) .2 Cliff Rosendahl, Brisbane  Hosted by AMC	<b>Symposium: A practical guide to sentinel node biopsy – Boulevard B2</b> Sentinel node biopsy has become an essential procedure for the surgeon involved with treating patients with advanced primary melanoma. At the Australasian Melanoma Conference there will be the presence of national and international experts involved in sentinel node biopsy, as well as surgeons experienced in the techniques in regional and metropolitan centres. We plan to use this expertise to run a session focusing on the practical issues around the interpretation of lymphoscintigraphy and the sentinel node biopsy procedure. <b>Chair:</b> Mark Smithers, Brisbane .1 <b>Radiology:</b> Kevin London, Sydney .2 <b>Regional surgeon:</b> David Ryan, Lismore .3 <b>Metro surgeon:</b> Alex van Akkooi, Sydney .4 <b>Panel discussions and case presentations</b> Hosted by AMC
9.00 - 10.30	<b>CONCURRENT SESSIONS 4</b>		
	<b>4.1 Locally advanced disease - multidisciplinary care - Boulevard Auditorium</b> <b>Chairs:</b> Rachel Roberts-Thomson, Adelaide & Melissa Eastgate, Brisbane .1 <b>The role of adjuvant therapy for stage II melanoma</b> - Rachel Robert-Thomson, Adelaide .2 <b>The role of adjuvant therapy for stage III melanoma</b> - Andrew Haydon, Melbourne .3 <b>The management of advanced desmoplastic melanoma including neoadjuvant therapy</b> - Megan Lyle, Cairns .4 <b>Management of in-transit melanoma</b> - Alexander van Akkooi, Sydney .5 <b>Update on electro-chemotherapy for in-transit melanoma</b> - James Clover, Ireland .6 <b>Discussion including case presentations</b> - Rachel Robert-Thomson, Andrew Haydon, Megan Lyle, Alexander van Akkooi	<b>4.2 The interchange between pathologists and clinicians – Boulevard B1</b> <b>Chairs:</b> Catriona McLean, Melbourne & Duncan Lambie, Brisbane .1 <b>Use and abuse of PRAME and SOX10 in diagnosis of melanocytic lesions</b> - Tessa Phillips .2 <b>When everything you thought you knew about Spitz goes BAM</b> - Benjamin Wood, Perth .3 <b>Reconceiving early detection of melanoma: the ACEMID cohort study</b> - Peter Ferguson, Sydney .4 <b>Interventions to improve histopathological agreement may reduce over calling and under calling of melanoma</b> - Matthew Gibson, Sydney .5 <b>The effects of providing dermoscopic images to pathologists interpreting melanocytic lesion</b> - Belinda Lai, Sydney .6 <b>Panel discussion</b> - Tessa Phillips, Benjamin Wood, Peter Ferguson, Matthew Gibson, Belinda Lai	<b>4.3 Workshop: Genetic counselling for primary melanoma – 09.00 - 10.45, Boulevard B2</b> <b>Chair:</b> Aideen McInerney-Leo, Brisbane  Restricted to the first 30 participants who will register for a one hour 45 minute workshop. Suitable for primary care / dermatologists and surgeons treating primary disease.
10.30 - 11.00	Morning Break		
11.00 - 12.30	<b>5. Plenary 2: Neoadjuvant immunotherapy: a gamechanger for melanoma patients - Boulevard Auditorium</b>		

	<p><b>Chairs:</b> Victoria Atkinson, Brisbane &amp; Andrew Barbour, Brisbane</p> <p><b>Perspectives:</b></p> <p><b>.1 The Medical Oncologist</b> - Georgina Long, Sydney</p> <p><b>.2 The Pathologist</b> - Richard Scolyer, Sydney</p> <p><b>.3 The Surgeon</b> – Alexander van Akkool, Sydney</p> <p><b>.4 Panel discussion:</b> Karen van Gorp, Alexander van Akkooi, Georgina Long, Richard Scolyer</p>		
12.30 - 1.45	Lunch Break		
	<b>INDUSTRY SESSIONS - 12.45 - 1.30</b>		
	<p><b>IS 2 Hot Topics in Melanoma - Boulevard Auditorium</b>  <i>A focus on treating in early-stage disease and clinical developments in melanoma.</i></p> <p><b>Panellist:</b> Matteo Carlino, Sydney</p> <p><b>Panellist:</b> Mark Smithers, Brisbane</p> <p><b>International Panellist:</b> Sapna Patel, Houston (USA)</p> <p><i>Sponsored by MSD</i></p>		
1.45 - 3.15	<b>CONCURRENT SESSIONS 5</b>		
	<p><b>5.3 Overdiagnosis – clinical realities - Boulevard Auditorium</b></p> <p><b>Chairs:</b> Solange Green, Brisbane &amp; Harald Kittler, Vienna (Austria)</p> <p><b>.1 The rapid rise in cutaneous melanoma diagnosis</b> - Adewole Adamson, Austin (USA)</p> <p><i>10min pre-record pres</i></p> <p><b>.2 Does overdiagnosis exist in the clinical practice</b> - Erin McMeniman, Brisbane</p> <p><b>.3 Use of imaging and AI in the context of overdiagnosis</b> - Victoria Mar, Melbourne</p> <p><b>.4 The role of dermatopathology in overdiagnosis</b> - Duncan Lambie, Brisbane</p> <p><b>.5 Psychological reactions to in situ melanoma</b> - Monika Janda, Brisbane</p> <p><b>.6 Overdiagnosis - which lesions should we leave</b> - Cliff Rosendahl, Brisbane</p> <p><b>.7 Panel Discussion:</b> Rod Flude, Erin McMeniman, Victoria Mar, Duncan Lambie, Monika Janda, Cliff Rosendahl</p>	<p><b>5.2 Radiation oncologist and melanoma – Boulevard B1</b></p> <p><b>Chairs:</b> Mark Pinkham, Brisbane &amp; Gishan Ratnayke, Brisbane</p> <p><b>.1 Role of RT for localized primary cutaneous melanoma and preinvasive disease</b> - Angela Hong, Sydney</p> <p><b>.2 Role of RT for resected and unresectable stage 3 cutaneous melanoma including ITD</b> - Tim Wang, Sydney</p> <p><b>.3 Role of SBRT in oligometastatic (oligo-persistent and -progressive) melanoma</b> - Sashendra Senthil, Melbourne</p> <p><b>.4 Stereotactic radiosurgery in melanoma</b> - Cecelia Gzell, Sydney</p> <p><b>.5 Radiotherapy and immunotherapy interactions to improve melanoma outcomes</b> - Gishan Ratnayke, Brisbane</p> <p><b>.6 Immune mapping of radio-responsive tumours using imaging mass cytometry</b> - Ruth Allen, Sydney</p>	<p><b>5.1 Issues in managing advanced melanoma and melanoma at unusual sites - Boulevard B2</b></p> <p><b>Chairs:</b> Victoria Atkinson, Brisbane &amp; Andrew Haydon, Melbourne</p> <p><b>.1 Has PD/LAG3 systemic therapies reached prime time for advanced disease?</b> - Georgina Long, Sydney</p> <p><b>.2 Is there ever a role for targeted therapy in advanced melanoma?</b> - Phil Parente, Melbourne</p> <p><b>.3 Mucosal melanoma/acral melanoma-novel therapies and novel approaches</b> - Matt Carlino, Sydney</p> <p><b>.4 Uveal melanoma - new and novel therapies</b> - Anthony Joshua, Sydney</p> <p><b>.5 Case Discussion</b> - Georgina Long, Phil Parente, Matt Carlino, Anthony Joshua</p>
3.15 - 3.45	Afternoon Tea		
3.45 - 5.15	<b>CONCURRENT SESSIONS 6</b>		
	<p><b>6.3 Clinico-pathologic cases - Boulevard Auditorium</b></p> <p><b>Chairs:</b> Duncan Lambie, Brisbane &amp; Catriona McLean, Melbourne</p> <p><i>Multiple datasets and topics for discussion with panel:</i></p> <p><b>.1 GP with skin interest:</b> Cliff Rosendahl, Brisbane &amp; Helena Rosengren, Townsville</p> <p><b>.2 Dermatology</b> - Victoria Mar, Melbourne &amp; Jim Muir, Brisbane</p> <p><b>.3 Pathology</b> - Louise Jackett, Melbourne &amp; Blake O'Brien, Brisbane</p> <p><b>.4 Surgery:</b> Chris Allan, Brisbane &amp; Sam Yang, Brisbane</p>	<p><b>6.2 Consumer session - Boulevard B1, 3.45 - 5.30</b></p> <p><b>Chairs:</b> Karen van Gorp, Adelaide &amp; Tamara Dawson, Melbourne</p> <p><b>What does the future of melanoma prevention and early detection look like?</b></p> <p><b>.1 Preventing melanoma, what does the future look like?</b> - David Whiteman, Brisbane</p> <p><b>.2 Diagnosing melanoma, what does the future look like?</b> - Helmut Schaidler, Brisbane</p> <p><b>.3 The current and future role of genetics in helping to identify people at high risk of developing melanoma</b> - Aideen McInerney-Leo, Brisbane</p> <p><b>.4 Q&amp;A Panel</b> - David Whiteman, Helmut Schaidler, Aideen McInerney-Leo</p> <p><b>What does the future of melanoma treatment and support look like?</b></p>	<p><b>6.1 Advanced skin cancer - Boulevard B2</b></p> <p><b>Chairs:</b> Ines da Silva, Sydney &amp; Kiarash Khosrotehrani, Brisbane</p> <p><b>.1 Merkel Cell- the role of adjuvant and neoadjuvant therapies</b> - Wen Xu, Brisbane</p> <p><b>.2 Translational research in keratinocytic cancers</b> - Kiarash Khosrotehrani, Brisbane</p> <p><b>.3 Surgical management of non melanoma skin cancers</b> - Sydney Ch'ng, Sydney</p> <p><b>.4 The role of adjuvant and neoadjuvant therapies for cutaneous SCC</b> - Ines da Silva, Sydney</p> <p><b>.5 Keratinocytic skin cancers in Transplant and immunosuppressed patients</b> - Miles Andrews, Melbourne</p> <p><b>.6 Discussion and case presentations</b> - focus on Merkel cell cancer and advanced keratinocytic cancers</p>
5.15 - 5.30		<p><b>.5 Advances in treatments for melanoma including neo adjuvant therapy, new systemic therapies, and treatment for earlier stage melanoma. Side effects and how oncologists can respond quickly</b> - Euan Walpole, Brisbane</p> <p><b>.6 The importance of supportive care for people with melanoma</b> - Claire Kelly, Gold Coast (National Support Manager, Melanoma Patients Australia)</p> <p><b>.7 Q&amp;A Panel</b> - Euan Walpole, Claire Kelly</p>	